NDA 020646 · Cephalon
Gabitril
Tiagabine Hydrochloride · Oral
NovelLast checked: Nov 19, 2026Latest source record: Mar 3, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Sep 30, 1997
Approved uses
1
Original approval plus efficacy supplements
Registered trials
19
6 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 30, 1997 Original approval · Type 1 - New Molecular Entity ReviewOther Important Information from FDA
8 products under this application
- GABITRIL · TIAGABINE HYDROCHLORIDE 8MG · TABLET, ORAL · Discontinued
- GABITRIL · TIAGABINE HYDROCHLORIDE 2MG · TABLET, ORAL · Prescription · TE AB
- GABITRIL · TIAGABINE HYDROCHLORIDE 16MG · TABLET, ORAL · Prescription · TE AB
- GABITRIL · TIAGABINE HYDROCHLORIDE 4MG · TABLET, ORAL · Prescription · TE AB
- GABITRIL · TIAGABINE HYDROCHLORIDE 10MG · TABLET, ORAL · Discontinued
- GABITRIL · TIAGABINE HYDROCHLORIDE 6MG · TABLET, ORAL · Discontinued
- GABITRIL · TIAGABINE HYDROCHLORIDE 20MG · TABLET, ORAL · Discontinued
- GABITRIL · TIAGABINE HYDROCHLORIDE 12MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Tiagabine" as an intervention, any sponsor and status, largest first.
- A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety DisorderPivotal-lookingCompleted
CephalonIndustry
NCT00236015 · 880 participants · Start Nov 2004
Drug: Gabitril · For: Anxiety Disorder
Sites: Mesa, Arizona; Peoria, Arizona; El Centro, California · 54 sites in all
- A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety DisorderPivotal-lookingCompleted
CephalonIndustry
NCT00236067 · 440 participants · Start Oct 2004
Drug: Gabitril · For: Generalized Anxiety Disorder
Sites: Birmingham, Alabama; Beverly Hills, California; Northridge, California · 21 sites in all
- A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety DisorderPivotal-lookingCompleted
CephalonIndustry
NCT00236054 · 440 participants · Start Oct 2004
Drug: Gabitril · For: Generalized Anxiety Disorder
Sites: Los Angeles, California; Newport Beach, California; San Diego, California · 19 sites in all
National Institute on Drug Abuse (NIDA)NIH
NCT00086255 · 140 participants · Start Oct 2002
Drug: Tiagabine · For: Cocaine-Related Disorders
Sites: Boston, Massachusetts; Cincinnati, Ohio; Dayton, Ohio · 4 sites in all
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00855738 · 111 participants · Start May 2007 · Primary completion Jun 2009
Drug: Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide · For: Focal Epilepsy
National Institute on Drug Abuse (NIDA)NIH
NCT00129298 · 80 participants · Start Dec 2004
Drug: Tiagabine · For: Cocaine-Related Disorders; Opiate Dependence
National Institute on Drug Abuse (NIDA)NIH
NCT00218166 · 78 participants · Start Aug 2001 · Primary completion May 2005
Drug: GABA Agonists · For: Cocaine-Related Disorders
Sites: Lexington, Kentucky
Oslo University HospitalAcademic, hospital or other
NCT00552526 · 60 participants (planned) · Start Nov 2007 · Primary completion Jan 2011
Drug: Antiepileptic drug (AED) · For: Epilepsy; Mental Retardation
Sites: Oslo, Norway
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Epilepsy.
Marson AG, Maguire M, Ramaratnam S · BMJ Clin Evid 2009 · Systematic Review
- Epilepsy (partial).
Maguire M, Marson AG, Ramaratnam S · BMJ Clin Evid 2011 · Systematic Review
- Epilepsy (partial).
Maguire M, Marson AG, Ramaratnam S · BMJ Clin Evid 2010 · Systematic Review
- Anticonvulsants for cocaine dependence.
Minozzi S, Cinquini M, Amato L, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force.
Tomson T, Battino D, Bromley R, et al. · Epileptic Disord 2022 · Systematic Review
- Tiagabine add-on for drug-resistant partial epilepsy.
Pulman J, Hutton JL, Marson AG · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Cephalon
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.